Skip to content

Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient

Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01045785
Enrollment
300
Registered
2010-01-11
Start date
2009-12-31
Completion date
2010-07-31
Last updated
2010-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Keywords

aspirin resistance, platelet function assay, dialysis, end stage renal disease

Brief summary

The purpose of this study is to determine whether aspirin resistance has impact on cardiovascular event in dialysis patient.

Detailed description

Dialysis patient inevitably suffered from uremic bleeding although improvement of dialysis care in the past decades. Physicians used to check bleeding time as a surrogate marker for uremic bleeding. However, bleeding time isn't accurate and as well known, is poorly correlated with clinical bleeding such as surgical bleeding. Platelet function assay (PFA) is a newly developed method to measure platelet aggregation in vitro and is validated in many sorts of platelet disorders. Recently, PFA was also used to evaluate aspirin responsiveness in patients who had taken aspirin. Our study is aim to investigate uremic thrombocytopathy via PFA of dialysis patient in Taiwan. Furthermore, we will study aspirin resistance in dialysis patient.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* dialysis \>3 months * Hb\>10 g/dl & Plt \> 10000

Exclusion criteria

* using medication which interfere PFA except aspirin * terminal disease such as malignancy * active vasculitis

Design outcomes

Primary

MeasureTime frame
cardiovascular event, bleeding event,and thrombosis1 year

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026